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Background: This study investigated the value of some clinicopathological parameters and 18 F-fluorodeoxyglucose-
positron emission tomography/computed tomography (18FDG-PET/CT) indices, including textural features, to predict
event-free survival (EFS) in estrogen receptor-positive/human epidermal growth factor receptor 2-negative (ER+/HER2-)
locally advanced breast cancer (BC) patients.
Methods: FDG-PET/CT indices and clinicopathological parameters were assessed before neoadjuvant chemotherapy
(NAC). After completion of chemotherapy, all patients had breast surgery with axillary lymph node dissection, followed
by radiation therapy and endocrine therapy for 5 years. EFS was estimated using the Kaplan-Meier method. A Cox
proportional hazard regression model was used for multivariate analysis.
Results: One hundred forty-three consecutive patients with stage II–III ER+/HER2- BC and without distant metastases
at baseline PET were included. High standardized uptake values (SUVs), were associated with shorter EFS (HR = 3.51,
P < 0.01 for SUVmax; HR = 2.76, P = 0.02 for SUVmean; and HR = 4.40 P < 0.01 for SUVpeak). Metabolically active tumor
volume (MATV, HR = 3.47, P < 0.01) and total lesion glycolysis (TLG, HR = 3.10, P < 0.01) were also predictive of EFS.
Homogeneity was not predictive (HR = 2.27, P = 0.07) and entropy had weak prediction (HR = 2.89, P = 0.02). Among
clinicopathological parameters, EFS was shorter in progesterone receptor (PR)-negative tumor (vs. PR-positive tumor;
HR = 3.25, P < 0.01); histology was predictive of EFS (lobular vs. ductal invasive carcinoma; HR = 3.74, P = 0.01) but not
tumor grade (grade 3 vs. grade 1–2; HR = 1.64, P = 0.32). Pathological complete response after NAC was not correlated
to the risk of relapse. Three parameters remained significantly associated with EFS in multivariate analysis. MATV
(HR = 1.01, P < 0.01), progesterone receptor expression (HR = 2.90, P = 0.03) and tumor histology (HR = 3.80, P = 0.02).
Conclusions: Baseline PET parameters measured before neoadjuvant treatment have prognostic values in ER+/HER2-
locally advanced breast cancer patients. After multivariate analysis, metabolically active tumor volume remains
significant while textural analysis of PET images is not of added value. Considering histopathological parameters, our
study shows that patients with PR-negative or lobular invasive tumor have poorer prognosis than patients with
PR-positive or ductal carcinoma, respectively.
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Neoadjuvant chemotherapy (NAC) is commonly used
for patients with large or locally advanced breast cancer
(BC). Pathological complete response (pCR) after NAC
(absence of residual invasive cells in the primary tumor
and axillary lymph nodes) is correlated with better sur-
vival [1]. This relationship between pathological re-
sponse and outcome is stronger in aggressive subtypes
such as the triple-negative (TN) BCs than in estrogen
receptor-positive/human epidermal growth factor recep-
tor 2-negative (ER+/HER2-) BCs [1]. Moreover, by defin-
ition, pCR can be only determined at the end of the
NAC. Various clinical and biological BC characteristics
assessed before treatment have shown a prognostic
value. For example, patients with lymph node involve-
ment have poorer prognosis than patients without lymph
node involvement (N0) and higher-grade tumors are
more aggressive than lower-grade tumors.
Positron emission tomography/computed tomography
(PET/CT) imaging could provide additional prognostic
information. It has been suggested that high baseline 18F-
fluorodeoxyglucose (18FDG) uptake assessed by high stan-
dardized uptake value (SUV) could be associated with
poor prognostic factors such as the high histological grade
[2] as well as worse survival [3, 4]. These previous studies
were focused on the prognostic value of SUVmax, without
testing other PET parameters. However, the prognostic
value of SUV measurement could be more limited in the
ER+/HER2- subtype than in other subtypes because lu-
minal tumors are somewhat less 18FDG-avid [2]. PET
parameters, taking into account metabolic volume mea-
surements, such as total lesion glycolysis (TLG), may im-
prove risk stratification in this specific subtype [5–8].
Recently, tumor textural analysis and heterogeneity
assessed with PET emerged also as potential prognostic fac-
tors in BC [9, 10]. These studies [9, 10] included patients
with different subtypes of breast cancer (triple-negative tu-
mors mixed with HER2+ tumors and/or with ER+ tumors),
receiving mixed treatments. Only one study examined the
relation between textural features and patient outcome [10].
Our study was focused in a homogenous and large
group of 143 patients with ER+/HER2- breast cancer, all
receiving the same treatment. We tested not only the
prognostic value of SUVmax but also the value of SUV-
mean, SUVpeak, metabolically active tumor volume
(MATV), total lesion glycolysis, and novel parameters
characterizing the tumor texture [homogeneity (H) and
entropy (E)]. The prognostic value of these PET features
was compared to clinicopathological prognostic factors.
Methods
Study design
We performed ancillary analysis of prospectively ac-
quired data in the frame of the ASAINT study(NCT02599974). ASAINT aimed at evaluating the diag-
nostic performance and the prognostic value of 18FDG-
PET/CT in patients with stage II or III breast cancer
undergoing neoadjuvant chemotherapy. The main object-
ive of the present study was to compare the value of some
clinicopathological parameters and PET-derived image in-
dices in predicting event-free survival (EFS) in the sub-
group of ER+/HER2- breast carcinoma. The secondary
objective was to examine the association between baseline
PET image parameters and tumor characteristics.
The study was approved by the institutional review
board with waivers of informed written consent for this
ad hoc analysis of image-derived data.
Tumor histology and immunohistochemistry
Breast cancer diagnosis was performed on a core needle
biopsy before neoadjuvant chemotherapy. Tumor grade
used the modified Scarff-Bloom-Richardson (SBR) sys-
tem. Tumors were estrogen receptor positive (ER+) if
showing moderate or high positivity (2+ or 3+) of at
least 10% of cells. The same criteria were used for pro-
gesterone receptor (PR). Tumors were HER2+ if more
than 30% of cells showed definite membrane staining
[11]. Control by fluorescence in situ hybridization or sil-
ver in situ hybridization was done for ambiguous cases.
Only patients with ER+/HER2- tumors were included.
18FDG-PET/CT imaging
Patients fasted for 6 hours and blood glucose level had
to be less than 7 mmol/L. Imaging started 60 minutes
after injection of 18FDG (5 MBq/kg); a 2 minutes per
bed acquisition was performed from mid-thigh level to
the base of the skull with the arms raised. The same
PET/CT scanner was used for all the patients: the Gem-
ini XL (Philips Medical Systems, Amsterdam, The
Netherlands). CT data were acquired first (120 kV; 100
mAs; 0.813 pitch factor; no contrast enhancement). CT
images were reconstructed with a pixel size of 1.17 mm.
Reconstruction section thickness was 3 mm and the re-
construction interval was 2 mm. PET images were re-
constructed with a isotropic voxel size of 4 mm.
Accurate registration of CT reconstructed and PET re-
constructed images was obtained by annual system
alignment calibration of the bed, CT gantry, and PET
gantry. The attenuation-corrected PET images were nor-
malized for injected dose and body weight, and subse-
quently converted into standardized uptake values
(SUVs), defined as: [tracer concentration (kBq/mL)] /
[injected activity (kBq)/patient body weight (g)].
PET-derived metabolic indices
For each patient, a large region of interest (ROI) encom-
passing the primary tumor and healthy breast tissue sur-
rounding the tumor was delineated manually by a
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used for this delineation, and ROIs were drawn only in
PET images. Then, the metabolically active tumor vol-
ume (MATV) was automatically extracted from the
manual delineation using software based on an adaptive
threshold method [12]. SUVmax (value of the voxel with
the highest SUV), SUVpeak (the mean of voxel intensities
in the region with the highest uptake corresponding to a
spherical ROI of 1 cm3 [13]), and SUVmean (mean value
of all the voxels within the segmented tumor) were auto-
matically calculated from the adaptive threshold seg-
mentation. Total lesion glycolysis (TLG) was defined as
MATV × SUVmean.
The texture analysis was performed on PET images
without using CT information. Texture parameters were
defined for each patient on the MATV. First, SUV values
were rescaled in 64 discrete bins [14]. We chose 64 bins
for the rescaling of the intensity values because a previ-
ous study showed this value was optimal for textural
analysis of PET images [14]. Then, three-dimensional
co-occurrence matrices were calculated from resampled
intensity volumes for a distance of one voxel (i.e., for
pairs of adjacent voxels).
Two textural parameters, entropy and homogeneity,
based on their robustness, their reproducibility, and their
potentiality to characterize tumor tissues and predict pa-
tient outcome, according to previous studies [9, 15, 16]
were calculated from three-dimensional co-occurrence
matrices and analyzed.
Entropy (E) quantifies the randomness of voxel inten-
sity distribution within the volume. The value of E is ex-
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P[i,j] is the number of voxel pairs having intensity i
and j in the co-occurrence matrix.
Homogeneity (H) quantifies the local homogeneity of
a pair of voxels. The value of H is high if the intensities
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Treatment
Patients received neoadjuvant chemotherapy with EC-D
(four cycles of epirubicin 75 mg/m2 plus cyclophospha-
mide 750 mg/m2 administered every 3 weeks, followed
by four courses of docetaxel 100 mg/m2). No neoadju-
vant endocrine therapy was used. After completion of
NAC, all the patients underwent breast surgery (breast-conserving surgery or mastectomy according to NAC re-
sponse) with axillary lymph node dissection. After sur-
gery, patients received locoregional radiation therapy
(tailored to disease stage and breast surgery results) and
adjuvant endocrine therapy for 5 years (tamoxifen in
premenopausal women or aromatase inhibitors in post-
menopausal women).
Pathology assessment and patient outcome
Pathological complete response (pCR) was defined as no
evidence of residual invasive cancer in breast tissues and
lymph nodes (ypT0/is ypN0). Absence of carcinoma in
situ was not mandatory to define pCR [1].
Date of baseline PET acquisition was considered as the
beginning of follow-up.
Event-free survival (EFS) was examined in patients free
of distant metastases at baseline staging. Events included
local, regional, or distant recurrences or death, which-
ever occurred first. During neoadjuvant chemotherapy,
patients were examined each two cycles. After breast
surgery, patients had follow-up clinical visits every
4 months for 2 years, then twice yearly.
Statistical analysis
All distributions were expressed as median for quantita-
tive data or count (percentage) for categorical data. As-
sociations between baseline tumor PET-derived images
parameters (SUVmax, SUVmean, SUVpeak, MATV, TLG,
homogeneity, and entropy) values and clinical or patho-
logical/biological parameters (tumor grade, progesterone
receptor expression, etc.) were examined with the
Wilcoxon rank sum test. Multiple corrections were per-
formed with the method of Benjamini-Hochberg.
Survival curves were estimated using the Kaplan-
Meier method. The relation between some clinicopatho-
logical tumor characteristics and EFS were examined
with the log-rank test. We also used the log-rank test to
examine the relation between PET-derived image param-
eters and EFS. Optimal PET parameter cutoff values for
predicting EFS were determined at 3 years of follow-up
with the Youden index after receiver-operating charac-
teristics curve analysis. Log-rank tests have been con-
trolled using the Hochberg’s procedure and hazard
ratios (HRs) were calculated with their 95% confidence
interval (CI).
We also performed a univariate analysis using Cox
proportional hazards logistic regression to identify prog-
nostic factors for EFS. Age and PET parameters were en-
tered as continuous variables. Then, on the basis of the
univariate analysis, we performed a stepwise multivariate
Cox analysis to identify independent prognostic factors.
We used a stepwise forward selection approach in which
the variable with the strongest association with EFS was
entered first, followed sequentially by other significant
Table 1 Overall characteristics of 143 ER+/HER2- breast cancer
patients without distant metastases
No. of patients (%)
Age in years
mean (SD), median [min, max] 51.4 (11.4), 50 [30; 78]
Histological type




Grade 1 7 (5%)
Grade 2 91 (64%)
Grade 3 42 (29%)















Stage IIA 25 (18%)
Stage IIB 49 (34%)
Stage IIIA 36 (25%)
Stage IIIB 30 (21%)
Stage IIIC 3 (2%)
ER+/HER2- estrogen receptor-positive/human epidermal growth factor receptor
2-negative, SD standard deviation
aClinical classification and stage after the clinical examination and before
18F-FDG-PET/CT according to the seventh edition of the AJCC Cancer
Staging Manual
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nonsignificant.
All tests were two-sided and P values below or equal
to 0.05 were considered statistically significant. Analyses
were performed using R statistical software (version
3.2.2) (R Foundation for Statistical Computing, Vienna,
Austria).
Results
From June 2006 to November 2015, 146 consecutive pa-
tients with clinical stage II or III ER+/HER2- BC pro-
spectively underwent 18FDG-PET/CT scanning before
starting NAC. Three patients were excluded because of
slight or no 18FDG uptake. The tumors of these three
patients could not be delineated. Table 1 shows the main
characteristics of the 143 included patients. The median
follow-up period was 44 months.
Relation between baseline tumor characteristics and
PET-derived indices
Patient age was not associated with SUV parameters,
MATV, and textural features, for the different subgroups
tested (≤40y vs. >40y and ≤50y vs. >50y) (Table 2).
Grade 3 tumors showed higher uptake than lower
grade (grade 1 + grade 2) tumors (median SUVmax 7.9 vs.
5.4, median SUVmean 4.2 vs. 3.1, median SUVpeak 6.4 vs.
4.4, P < 0.01 in all the cases). 18FDG uptake seemed to
be higher in invasive ductal carcinoma (IDC) than in in-
vasive lobular carcinoma (ILC) but the difference was
not significant (Table 2); only seven patients had ILC.
Neither tumor characteristics according to the TNM
classification of malignant tumors (clinical T score) nor
lymph node characteristics according to the TNM classi-
fication (N score) were associated with the degree of
18FDG tumor uptake (Table 2).
On the contrary, as expected, MATV and TLG were
significantly higher in T3 (tumor size > 5 cm) than in T2
tumor (tumor size ≤ 5 cm). Similarly, entropy and homo-
geneity were associated with tumor size. After correction
for multiple testing, no significant relation was observed
between the textural features and the biological or histo-
logical tumor characteristics (Table 2).
Relation between baseline tumor characteristics or
pathology findings after NAC and EFS
Twenty patients relapsed. Distant metastases were de-
tected in 15 patients. Sites of distant metastases were
bone (N = 9), liver (N = 7), distant lymph nodes (N = 4),
pleura (N = 2), brain (N = 2), and skin (N = 1). Four pa-
tients with distant metastases died.
T score based on clinical examination before 18FDG-
PET/CT was not associated with EFS (T1–2 vs. T3–4,
log-rank P = 0.3). The same observation was made with
clinical N score (N0 vs. N1–2–3, log-rank P = 0.13).Finally, clinical stage determined before PET/CT scan-
ning was not associated with EFS (stage II vs. stage III,
log-rank P = 0.13).
Among baseline tumor characteristics determined at
initial biopsy, progesterone receptor expression was
associated with EFS, with higher risk of relapse in pa-
tients with PR- tumors (HR = 3.25, log-rank P < 0.01;
Fig. 1). Patients with ILC had shorter EFS in compari-
son to patients with IDC (HR = 3.74, log-rank P = 0.01).
With regard to the seven patients with an ILC, none
reached pCR while four relapsed. SBR grade (grade 3
Table 2 Relation between some clinical or tumor characteristics and tumor PET-derived image parameters in 143 patients with ER
+/HER2- breast cancer
Age Tumora Lymph nodesa Histology Grade PR expression
≤40 >40 ≤50 >50 T2 T3 N0 N+ IDC ILC 1–2 3 Neg Pos
No. patients 27 116 74 69 53 56 58 85 129 7 98 42 55 88
SUVmax med 5.4 6.8 6.5 6.6 5.2 5.9 6.1 6.6 6.8 4.8 5.4 7.9 7.2 5.7
P 0.31 0.63 0.56 0.79 0.43 <0.01 0.06
SUVmean med 3.1 3.6 3.4 3.6 2.9 3.3 3.5 3.5 3.6 3.0 3.1 4.2 4.0 3.2
P 0.36 0.67 0.59 0.77 0.31 <0.01 0.06
SUVpeak med 4.3 5.3 5.1 5.1 4.1 4.9 4.9 5.1 5.2 4.4 4.4 6.4 5.7 4.5
P 0.32 0.60 0.44 0.81 0.63 <0.01 0.05b
MATV med 10.1 11.2 11.0 9.6 6.7 10.8 9.2 11.3 10.1 32.5 10.9 10.4 13.9 9.1
P 0.33 0.86 <0.01 0.24 0.02b 0.83 0.03b
TLG med 27.2 39.0 33.5 35.2 20.1 33.5 32.7 40.5 32.8 74.6 32.1 44.8 46.3 28.2
P 0.22 0.86 <0.01 0.41 0.16 0.05b 0.01b
H med 0.12 0.12 0.12 0.12 0.11 0.12 0.12 0.12 0.12 0.14 0.12 0.12 0.13 0.12
P 0.81 0.87 0.02 0.10 0.09 0.73 0.12
E med 3.5 3.8 3.7 3.6 3.2 3.7 3.5 3.8 3.6 4.8 3.7 3.7 4.0 3.5
P 0.18 0.97 <0.01 0.25 0.02b 0.70 0.02b
P value for comparison of median values with the Wilcoxon rank sum test. Bold numerals correspond to P values keeping statistically significant after multiple
corrections from Benjamini-Hochberg
PET positron emission tomography, ER+/HER2- estrogen receptor-positive/human epidermal growth factor receptor 2-negative, PR progesterone receptor, IDC inva-
sive ductal carcinoma, ILC invasive lobular carcinoma, SUV standardized uptake value, MATV metabolically active tumor volume, TLG total lesion glycolysis,
H homogeneity, E entropy
aClinical classification according to the seventh edition of the AJCC Cancer Staging Manual
bNot significant after correction for multiple testing
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0.32; Fig. 1).
At completion of NAC, only 12 patients (8%) had
pCR. No relapse was observed in the 12 women whose
tumors reached pCR (0/12 vs. 20/131, P = 0.36). How-
ever pCR was not found to be significantly associated
with EFS (log-rank P = 0.18; Fig. 1).
Relation between PET-derived parameters and EFS
A high SUVmax at baseline was associated with shorter EFS
(HR = 3.51, log-rank P < 0.01; Fig. 2). The Youden index
method allowed identifying an optimal cutoff value of 8.3.
Nine patients over 39 (23.1%) with baseline tumor SUV-
max > 8.3 relapsed vs. 11/104 patients (10.6%) with baseline
tumor SUVmax ≤ 8.3. The 3-year EFS was 78.4% in patients
with baseline tumor SUVmax > 8.3 (vs. 94.0% in those with
SUVmax ≤ 8.3). The cutoff value of 10, previously published
[5], was also found to be significantly associated with EFS
(log-rank P < 0.01). High tumor SUVmean and mostly high
tumor SUVpeak were also associated with shorter EFS (HR
= 2.76, P = 0.02 and HR= 4.40, P < 0.01, respectively, Fig. 2).
Tumor volume parameters were also predictive of
EFS, with higher risk of recurrence in the case of larger
tumor (HR = 3.47 and P < 0.01 for MATV; HR = 3.10
and P < 0.01 for TLG; Fig. 3).
Among tumor texture parameters, entropy was pre-
dictive of EFS (HR = 2.89, log-rank P = 0.02) whilehomogeneity did not have a significant value (HR = 2.27,
log-rank P = 0.07) (Fig. 3).
The associations between SUVmax, SUVpeak, SUVmean,
MATV, TLG, and entropy with EFS remain significant
after Hochberg’s procedure.
Comparison of PET parameters and tumor characteristics
to predict EFS
A Cox proportional hazard regression model with PET pa-
rameters and tumor characteristics was used for univariate
analysis to predict EFS (Table 3). The clinical parameters
age (P = 0.10), grade (P = 0.60), tumor classification (P =
0.09), lymph node classification (P = 0.24) and stage (P =
0.05, not significant after multiple testing correction) were
not prognostic factors of EFS in univariate analysis and
then not included in the multivariate model. The followings
parameters were significantly associated with EFS on uni-
variate analysis, after multiple testing corrections (Benja-
mini-Hochberg procedure): histology (P = 0.02), PR
expression (P = 0.01), SUVmax (P < 0.01), SUVmean (P =
0.01), SUVpeak (P < 0.01), MATV (P < 0.01), TLG (P < 0.01),
entropy (P = 0.02), and homogeneity (P = 0.02). All those
parameters were subjected to multivariate analysis. Three
parameters remained significantly associated with EFS in
multivariate analysis (Table 3): MATV (HR= 1.01, P <
0.01), progesterone receptor expression (HR = 2.90, P =
0.03) and tumor histology (HR = 3.80, P = 0.02).
Fig. 1 Relation between event-free survival (EFS) and histological tumor type (a), tumor grade (b), progesterone receptor (PR) expression (c) and
pathology findings after neoadjuvant chemotherapy (d), in 143 patients with ER+/HER2- breast cancer. IDC invasive ductal carcinoma, ILC invasive
lobular carcinoma, pCR pathological complete response
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In patients with breast cancer of mixed phenotypes, several
teams observed that the change in SUV values early during
neoadjuvant treatment could be a good indicator of patho-
logical response and potentially outcome [8, 17]. However,
others studies suggested that baseline 18FDG uptake, which
would avoid performing a second examination, could also
be of interest to predict patient outcome, especially in ER
+/HER2- BC [4, 5]. Our study was designed to evaluate the
predictive value of novel PET parameters based on texture
analysis (entropy and homogeneity). It is unclear what the
significance of the textural modification under treatment is
and how to measure this change. Therefore we decided to
focus our study on the predictive value of PET parameters
measured at baseline.
ER+/HER2- BC has less intense 18FDG uptake than
some other phenotypes such as TN carcinoma [2, 18].
Nevertheless, several PET-derived indices measured be-
fore treatment were predictive of event-free survival in
our cohort of 143 patients with no evidence of distant
metastases at initial evaluation. In those patients, theextent of pathological response measured after the neo-
adjuvant chemotherapy was not predictive of EFS.
Complete pathological response to NAC is a rare event
in ER+/HER- breast cancer (only 8% of patients in the
present series). Although no relapse was observed in the
12 women whose tumors reached pCR (0/12 vs. 20/131,
P = 0.36), pCR was not found to be significantly associ-
ated with EFS (log-rang P = 0.18; Fig. 1).
Among baseline tumor characteristics, tumor grade
was not predictive of EFS. Progesterone receptor nega-
tivity was associated with a higher risk of relapse, as in a
previously reported series [19]. Histological type was
also associated with patient outcome with shorter EFS in
the case of invasive lobular carcinoma in comparison to
ductal carcinoma (log-rank P = 0.01). Loibl et al. ob-
served that patients with ILC had a low chance of
obtaining a pCR although it was not well correlated with
further outcome [20]. In another study focusing on the
ER+/HER2- subgroup, patients with ILC had shorter
disease-free survival and overall survival than patients
with IDC [21], in congruence with our data.
Fig. 2 Relation between event-free survival (EFS) and baseline tumor
standardized uptake value (SUV)max (a), SUVmean (b), SUVpeak (c) in
143 patients with ER+/HER2- breast cancer
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higher risk of early recurrence. The 3-year EFS was
78.4% in patients with baseline tumor SUVmax > 8.3 (vs.
94.0% in those with SUVmax ≤ 8.3). However, in multi-
variate analysis, MATV was the solely PET parameter
significantly associated with EFS (Table 3). Son et al. ob-
served also that MATV was predictive of patient out-
come [10]: in 123 patients with IDC, among four PET
parameters (SUVmax, MATV, TLG, and heterogeneity), only
MATV and heterogeneity were predictive of overall survival[10]. However, the heterogeneity factor used was defined as
“a derivative of a volume threshold function from 40% to
80% of the SUVmax” and was reported to be highly corre-
lated with MATV (r = 0.96) [10]. This factor was only a sur-
rogate measurement of volume and it cannot be considered
as a measurement of intratumor heterogeneity. Parameters
that characterize the tumor texture did not further improve
the prediction of EFS in our study.
We determined MATV according to an adaptive thresh-
old method [12]. This approach has demonstrated high
accuracy, robustness, and reproducibility [12]. Our results
might have been different if we had used a less accurate
method such as fixed threshold-based approaches. In a
group of 142 women with breast cancer of mixed pheno-
types, it was found that SUVmax had superior predictive
value than volume parameters (namely TLG) derived
through manual contouring and fixed threshold [22].
Our study has some limitations. This was a single institu-
tion experience. The follow-up period was still limited (me-
dian = 44 months) when considering the fact that many
recurrences in patients with ER+/HER2- tumors occur be-
tween 5 and 10 years after treatment, or even later.
We included patients with large tumors. Our results could
not be observed in small tumors, for which partial volume
effect has a significant impact in SUV value measurement.
We focused our analysis on ER+/HER2- breast cancers.
This subgroup is based on immunohistochemistry tests
and defines patients receiving a homogeneous treatment
regimen [5, 7, 8]. Others categorizations could have been
considered and, in particular, ER+ BC can also be dichoto-
mized into luminal A (ER+/HER2- breast tumor, with low
grade and low proliferation) and luminal B (which re-
groups high proliferative ER+/HER2- breast carcinoma
and some ER+/HER2+ tumors). We decided to restrict
analysis to ER+/HER2- breast cancer and excluded HER2
+ tumors because these patients receive specific targeted
treatments (trastzumab) and have specific 18FDG-PET re-
sponse characteristics to NAC [23–26].
Optimal PET parameter cutoff values for predicting
EFS were determined at 3 years of follow-up with the
Youden index after receiver-operating characteristics
curve analysis. Our thresholds are specific of our popu-
lation of ER+/HER2- BC patients. At baseline, 18FDG
uptake depends on the breast cancer phenotype [2]. For
example, triple-negative breast cancer has higher uptake
than luminal breast tumors. Therefore, the thresholds of
SUV values should be potentially higher in the case of
triple-negative tumors.
We focused our analysis on seven semi-quantitative
metabolic PET-derived parameters calculated from static
acquisitions. Fully quantitative kinetic analysis may also
be helpful for therapeutic response prediction [27] but,
kinetic measurements are much more difficult to apply
in clinical practice.
Fig. 3 Relation between event-free survival (EFS) and baseline tumor metabolically active tumor volume (MATV) (a), total lesion glycolysis (TLG)
(b), homogeneity (H) (c), and entropy (E) (d) in 143 patients with ER+/HER2- breast cancer
Table 3 Uni- and multivariate analysis using metabolic PET parameters and clinicopathologic factors for EFS
Parameters Univariate analysis Multivariate analysis
P value P value Hazard ratio (95% CI)
Age 0.10 Not included
Histology 0.02 0.02 3.80 (1.22–11.80)
Grade 0.60 Not included
PR expression 0.01 0.03 2.90 (1.12–7.49)
Tumor classification 0.09 Not included
Lymph node classification 0.24 Not included
Stage 0.05a Not included
SUVmax <0.01 Not retained in the final model
SUVmean 0.01 Not retained in the final model
SUVpeak <0.01 Not retained in the final model
MATV <0.01 <0.01 1.01 (1.00–1.02)b
TLG <0.01 Not retained in the final model
Entropy 0.02 Not retained in the final model
Homogeneity 0.02 Not retained in the final model
P value corresponds to Cox proportional hazard regression model. Hazard ratios were calculated with their 95% confidence interval (CI). Bold numerals correspond
to statistically significant P values
PET positron emission tomography, EFS event-free survival, PR progesterone receptor, SUV standardized uptake value, MATV metabolically active tumor volume,
TLG total lesion glycolysis, H homogeneity, E entropy
aNot significant after multiple testing correction
bHR for MATV was calculated on a continuous variable (if MATV increase from 1 ml, the risk of relapse increase of 1%)
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Groheux et al. Breast Cancer Research  (2017) 19:3 Page 9 of 10Finally, some PET tracers other than 18FDG could also
be of interest in BC. In particular, 16α-18F-fluoro-17β-es-
tradiol (18FES) could be efficient in luminal tumors [28].
Conclusions
In a series of 143 patients, our study confirms that baseline
PET parameters measured before neoadjuvant treatment
have prognostic values in ER+/HER2- locally advanced
breast cancer patients. After multivariate analysis, metabol-
ically active tumor volume remains significant while tex-
tural analysis of PET images is not of added value. These
findings suggest that 18FDG PET image-derived indices,
notably volume parameters, may be helpful to plan patient
follow-up, as well as to select high-risk patients within trials
investigating novel treatment strategies.
Considering histopathological parameters, our study
shows that patients with PR-negative or lobular invasive
tumor have poorer prognosis than patients with PR-
positive or ductal carcinoma, respectively.
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